$7.87 Billion is the total value of Baker Brothers Advisors's 108 reported holdings in Q1 2014. The portfolio turnover from Q4 2013 to Q1 2014 was 30.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SGEN | Buy | Seattle Genetics, Inc. | $944,887,000 | +14.2% | 20,739,426 | +0.0% | 12.01% | +3.0% |
| GEVA | Buy | Synageva Biopharma Corp. | $883,480,000 | +32.9% | 10,648,182 | +3.7% | 11.23% | +19.8% |
| PCYC | Buy | Pharmacyclics Inc. | $875,711,000 | -5.1% | 8,737,888 | +0.2% | 11.13% | -14.4% |
| INCY | Buy | Incyte Corp. | $793,999,000 | +5.9% | 14,835,559 | +0.2% | 10.09% | -4.5% |
| ACAD | Buy | Acadia Pharmaceuticals Inc. | $498,313,000 | -0.1% | 20,481,442 | +2.6% | 6.33% | -9.9% |
| Salix 2.75% 5/15/15conv bonds | $491,957,000 | +13.9% | 219,440,000 | 0.0% | 6.25% | +2.8% | ||
| GHDX | Buy | Genomic Health Inc. | $359,650,000 | -10.0% | 13,654,150 | +0.0% | 4.57% | -18.8% |
| Incyte Genomics Notes 1.25% 11/15/2020 144Aconv bonds | $350,417,000 | +5.2% | 274,500,000 | 0.0% | 4.45% | -5.1% | ||
| Incyte Genomics Notes 0.375% 11/15/2018 144Aconv bonds | $326,745,000 | +5.4% | 259,000,000 | 0.0% | 4.15% | -4.9% | ||
| New | Incyte Genomics Notes 4.75% 10/1/2015 144Aconv bonds | $245,887,000 | – | 40,446,000 | +100.0% | 3.12% | – | |
| ITMN | Buy | Intermune Inc. | $144,752,000 | +6449.9% | 4,324,843 | +2783.2% | 1.84% | +5835.5% |
| Buy | Auxilium 1.5% 7/15/2018conv bonds | $128,796,000 | +33.7% | 97,990,000 | +12.5% | 1.64% | +20.5% | |
| BMRN | Sell | Biomarin Pharmaceuticals | $128,455,000 | -5.9% | 1,883,230 | -3.0% | 1.63% | -15.2% |
| XOMA | Buy | Xoma Corp. | $120,130,000 | -22.5% | 23,057,572 | +0.1% | 1.53% | -30.1% |
| Intermune Inc Notes 2.5% 12/15/17conv bonds | $107,856,000 | +92.1% | 41,000,000 | 0.0% | 1.37% | +73.3% | ||
| ICPT | Sell | Intercept Pharmaceuticals, Inc. | $84,550,000 | +241.3% | 256,375 | -29.3% | 1.08% | +208.0% |
| Biomarin Pharmaceuticals Notes 1.875% 4/23/2017conv bonds | $77,127,000 | -2.8% | 22,898,000 | 0.0% | 0.98% | -12.4% | ||
| HALO | Sell | Halozyme Therapeutics Inc. | $72,366,000 | -23.3% | 5,698,139 | -9.5% | 0.92% | -30.8% |
| VNDA | Sell | Vanda Pharmaceuticals, Inc. | $72,243,000 | +21.5% | 4,445,696 | -7.2% | 0.92% | +9.5% |
| Gilead 1.625% 5/1/16conv bonds | $66,903,000 | -5.7% | 21,500,000 | 0.0% | 0.85% | -14.9% | ||
| BCRX | Sell | Biocryst Pharmaceuticals Inc. | $62,073,000 | +21.9% | 5,867,031 | -12.4% | 0.79% | +9.9% |
| ANAC | Buy | Anacor Pharmaceuticals | $61,937,000 | +47.6% | 3,095,318 | +23.8% | 0.79% | +33.2% |
| Medivation 2.625% 4/1/17conv bonds | $56,288,000 | -2.6% | 39,500,000 | 0.0% | 0.72% | -12.3% | ||
| RPRX | Repros Therapeutics | $49,293,000 | -3.1% | 2,778,654 | 0.0% | 0.63% | -12.6% | |
| QCOR | Sell | Questcor Pharmaceuticals, Inc. | $46,603,000 | +10.3% | 717,745 | -7.5% | 0.59% | -0.5% |
| MRTX | Mirati Therapeutics Inc. | $45,388,000 | +14.7% | 2,380,074 | 0.0% | 0.58% | +3.4% | |
| DSCI | Buy | Derma Sciences | $44,851,000 | +62.0% | 3,537,137 | +38.2% | 0.57% | +46.2% |
| CERS | Cerus | $40,585,000 | -25.6% | 8,455,306 | 0.0% | 0.52% | -32.9% | |
| GILD | Gilead Sciences Inc. | $39,406,000 | -5.6% | 556,108 | 0.0% | 0.50% | -14.9% | |
| ACOR | New | Acorda Therapeutics, Inc. | $37,910,000 | – | 1,000,000 | +100.0% | 0.48% | – |
| CHTP | Buy | Chelsea Therapeutics | $37,317,000 | +45.2% | 6,760,394 | +16.7% | 0.47% | +30.9% |
| CLVS | Sell | Clovis Oncology | $36,712,000 | +14.8% | 529,990 | -0.1% | 0.47% | +3.5% |
| Intermune Inc Notes 5% 3/1/15conv bonds | $30,590,000 | +56.7% | 16,860,000 | 0.0% | 0.39% | +41.5% | ||
| HRTX | New | Heron Therapeutics, Inc. | $30,153,000 | – | 2,167,784 | +100.0% | 0.38% | – |
| Salix 1.5% 3/15/19conv bonds | $25,289,000 | +13.1% | 15,000,000 | 0.0% | 0.32% | +1.9% | ||
| AEGR | Buy | Aegerion Pharmaceuticals | $23,702,000 | -33.2% | 513,922 | +2.8% | 0.30% | -39.8% |
| DYAX | Buy | Dyax Corp. | $22,735,000 | +48.9% | 2,531,766 | +24.9% | 0.29% | +34.4% |
| AVNR | Buy | Avanir Pharmaceuticals | $21,250,000 | +16.5% | 5,790,139 | +6.7% | 0.27% | +5.1% |
| XNPT | Buy | Xenoport | $20,856,000 | +250.8% | 4,034,112 | +290.1% | 0.26% | +215.5% |
| PGNX | Buy | Progenics Pharmaceuticals, Inc. | $18,200,000 | -18.7% | 4,449,797 | +5.9% | 0.23% | -26.7% |
| AQXP | New | Aquinox Pharmaceuticals, Inc. | $15,427,000 | – | 1,211,851 | +100.0% | 0.20% | – |
| TGTX | Sell | TG Therapeutics | $14,911,000 | +73.8% | 2,160,965 | -1.8% | 0.19% | +57.0% |
| Biomarin Pharmaceuticals Notes 0.75% 10/15/2018conv bonds | $13,699,000 | +3.3% | 12,500,000 | 0.0% | 0.17% | -7.0% | ||
| KYTH | Sell | Kythera Biopharmaceuticals | $12,375,000 | +5.8% | 311,255 | -0.6% | 0.16% | -4.8% |
| ARWR | Sell | Arrowhead Research Corp. | $12,020,000 | -64.1% | 732,062 | -76.3% | 0.15% | -67.6% |
| INSM | Sell | Insmed Inc. | $10,549,000 | -22.1% | 554,050 | -30.4% | 0.13% | -29.8% |
| TKMR | Sell | Tekmire Pharmaceuticals Corp. | $10,405,000 | +161.1% | 484,156 | -3.2% | 0.13% | +135.7% |
| SGMO | Buy | Sangamo Biosceiences, Inc. | $9,452,000 | +60.4% | 522,764 | +23.2% | 0.12% | +44.6% |
| SGYPQ | Sell | Synergy Pharmaceuticals | $9,336,000 | -36.4% | 1,758,271 | -32.6% | 0.12% | -42.5% |
| OMER | Buy | Omeros Corp. | $9,098,000 | +32.5% | 753,804 | +23.9% | 0.12% | +19.6% |
| PRTA | Sell | Prothena Corp. PLC | $8,817,000 | -1.3% | 230,142 | -31.7% | 0.11% | -11.1% |
| THLD | Sell | Threshold Pharma | $8,693,000 | +0.5% | 1,826,358 | -1.4% | 0.11% | -9.8% |
| QLTI | QLT Inc. | $8,539,000 | -0.2% | 1,535,863 | 0.0% | 0.11% | -9.9% | |
| DSCO | Sell | Discovery Laboratories Inc. | $7,852,000 | -6.2% | 3,652,117 | -1.8% | 0.10% | -15.3% |
| AGIO | Sell | Agios Pharmaceuticals | $7,826,000 | +58.8% | 199,893 | -2.8% | 0.10% | +43.5% |
| GALT | Buy | Galectin Therapeutics Inc. | $7,655,000 | +841.6% | 500,000 | +397.0% | 0.10% | +781.8% |
| INFI | New | Infinity Pharmaceuticals Inc. | $7,420,000 | – | 624,050 | +100.0% | 0.09% | – |
| NBIX | New | Neurocrine Biosciences, Inc. | $7,211,000 | – | 447,874 | +100.0% | 0.09% | – |
| STML | Sell | Stemline Therapeutics Inc. | $6,895,000 | -47.9% | 338,671 | -49.8% | 0.09% | -52.7% |
| AMBI | Ambit Biosciences Corp. | $6,821,000 | -5.4% | 747,954 | 0.0% | 0.09% | -14.7% | |
| ARRY | Sell | Array Biopharma Inc. | $6,739,000 | -10.3% | 1,433,797 | -4.4% | 0.09% | -18.9% |
| BOTA | Sell | Biota Pharmaceuticals | $6,763,000 | +42.8% | 1,106,910 | -2.1% | 0.09% | +28.4% |
| ZGNX | Sell | Zogenix, Inc. | $6,687,000 | -29.3% | 2,350,400 | -14.6% | 0.08% | -36.1% |
| IDRA | Sell | Idera Pharmaceuticals Inc. | $6,581,000 | -55.2% | 1,613,076 | -49.1% | 0.08% | -59.4% |
| AERI | Sell | Aerie Pharmaceuticals | $6,343,000 | +17.7% | 299,356 | -0.2% | 0.08% | +6.6% |
| XNCR | Sell | Xencor | $6,362,000 | +26.6% | 542,363 | -1.4% | 0.08% | +14.1% |
| NVAX | Sell | Novavax Inc. | $5,542,000 | -15.9% | 1,223,362 | -4.9% | 0.07% | -24.7% |
| IRWD | Sell | Ironwood Pharmaceuticals | $5,497,000 | -13.3% | 446,160 | -18.3% | 0.07% | -21.3% |
| RGDO | New | Regado | $5,008,000 | – | 400,000 | +100.0% | 0.06% | – |
| LGND | New | Ligand Pharmaceuticalsclass b | $4,937,000 | – | 73,400 | +100.0% | 0.06% | – |
| EPZM | Sell | Epizyme Inc. | $4,873,000 | +6.5% | 214,012 | -2.7% | 0.06% | -3.1% |
| RARE | New | Ultragenyx Pharmaceuticals | $4,889,000 | – | 100,000 | +100.0% | 0.06% | – |
| PTLA | Sell | Portola Pharmaceuticals, Inc. | $4,729,000 | -18.2% | 182,591 | -18.6% | 0.06% | -25.9% |
| RXDX | New | Ignyta | $4,739,000 | – | 571,000 | +100.0% | 0.06% | – |
| CYTR | New | Cytrx Corp. | $4,712,000 | – | 1,350,000 | +100.0% | 0.06% | – |
| OSIR | Sell | Osiris Therapeutics Inc. | $4,747,000 | -21.3% | 361,530 | -3.7% | 0.06% | -29.4% |
| BLUE | Buy | Bluebird Bio Inc. | $4,508,000 | +87.8% | 198,260 | +73.2% | 0.06% | +67.6% |
| CLTX | New | Celsus Therapeutics | $4,374,000 | – | 673,887 | +100.0% | 0.06% | – |
| ISIS | Sell | Isis Pharmaceuticals, Inc. | $4,161,000 | -57.7% | 96,303 | -61.0% | 0.05% | -61.9% |
| RTRX | New | Retrophin Inc. | $4,194,000 | – | 197,178 | +100.0% | 0.05% | – |
| FURX | New | Furiex Pharmaceuticals, Inc. | $3,507,000 | – | 40,309 | +100.0% | 0.04% | – |
| BDSI | Sell | BioDelivery Sciences Intl. Inc. | $3,553,000 | -28.7% | 421,005 | -50.2% | 0.04% | -35.7% |
| ENTA | Sell | Enanta Pharmaceuticals | $3,237,000 | +8.8% | 80,957 | -25.8% | 0.04% | -2.4% |
| MGNX | Sell | Macrogenics, Inc. | $2,676,000 | -2.4% | 96,165 | -3.8% | 0.03% | -12.8% |
| LJPC | New | La Jolla Pharmaceuticals, Inc. | $2,394,000 | – | 221,631 | +100.0% | 0.03% | – |
| SNTA | Synta Pharmaceuticals | $2,155,000 | -17.7% | 500,000 | 0.0% | 0.03% | -27.0% | |
| MSTX | New | Mast Therapeutics, Inc. | $2,040,000 | – | 3,000,000 | +100.0% | 0.03% | – |
| OSUR | Sell | Orasure Technologies Inc. | $1,870,000 | +22.1% | 234,664 | -3.6% | 0.02% | +9.1% |
| RIGL | Sell | Rigel Pharmaceuticals | $1,870,000 | +31.2% | 481,972 | -3.6% | 0.02% | +20.0% |
| KPTI | Sell | Karyopharm Therapeutics | $1,825,000 | +29.8% | 59,095 | -3.6% | 0.02% | +15.0% |
| AKAOQ | New | Achaogen Inc. | $1,546,000 | – | 100,000 | +100.0% | 0.02% | – |
| AUXL | New | Auxilium Pharmaceuticals, Inc. | $1,591,000 | – | 58,544 | +100.0% | 0.02% | – |
| ACHN | Sell | Achillion | $1,442,000 | -4.5% | 438,337 | -3.7% | 0.02% | -14.3% |
| OPHT | Sell | Ophthotech Corp. | $1,314,000 | -60.6% | 36,776 | -64.3% | 0.02% | -63.8% |
| CPRX | New | Catalyst Pharmaceuticals, Inc. | $1,288,000 | – | 569,853 | +100.0% | 0.02% | – |
| ZIOP | Sell | Ziopharm Oncology Inc. | $1,120,000 | +1.5% | 244,619 | -3.8% | 0.01% | -12.5% |
| FOLD | Sell | Amicus Therapeutics | $997,000 | -17.6% | 481,697 | -6.5% | 0.01% | -23.5% |
| RCPT | Sell | Receptos Inc. | $1,002,000 | -65.4% | 23,900 | -76.1% | 0.01% | -68.3% |
| XLRN | Sell | Acceleron Pharma Inc. | $992,000 | -16.5% | 28,765 | -4.1% | 0.01% | -23.5% |
| TSRO | Tesaro Inc. | $920,000 | +4.3% | 31,218 | 0.0% | 0.01% | 0.0% | |
| GERN | Geron Corp. | $837,000 | -56.1% | 402,629 | 0.0% | 0.01% | -59.3% | |
| ALNY | New | Alnylam Pharmaceuticals, Inc. | $779,000 | – | 11,600 | +100.0% | 0.01% | – |
| VTUS | Sell | Ventrus Biosciences, Inc. | $535,000 | -88.5% | 417,690 | -65.6% | 0.01% | -89.2% |
| QURE | New | Uniquere B.V. | $477,000 | – | 30,672 | +100.0% | 0.01% | – |
| SLXP | Salix Pharmaceuticals | $375,000 | +15.0% | 3,621 | 0.0% | 0.01% | 0.0% | |
| FPRX | Five Prime Therapeutics Inc. | $390,000 | +17.1% | 19,823 | 0.0% | 0.01% | 0.0% | |
| CCXI | Chemocentryx Inc. | $332,000 | +14.5% | 50,000 | 0.0% | 0.00% | 0.0% | |
| CYCCP | Sell | Cyclacel Pharmaceuticals Pfd. Conv. Ex 6%pfd conv ex | $113,000 | -41.5% | 13,253 | -36.8% | 0.00% | -66.7% |
| FMI | Exit | Foundation Medicine Inc. | $0 | – | -20,000 | -100.0% | -0.01% | – |
| UTHR | Exit | United Therapeutics Corp. | $0 | – | -20,000 | -100.0% | -0.03% | – |
| PBYI | Exit | Puma Biotechnology | $0 | – | -25,000 | -100.0% | -0.04% | – |
| LGND | Exit | Ligand Pharmaceuticals Inc.class b | $0 | – | -73,400 | -100.0% | -0.05% | – |
| GWPH | Exit | GW Pharmaceuticals PLCads | $0 | – | -94,172 | -100.0% | -0.06% | – |
| Exit | Infinity Pharmaceuticals Inc. | $0 | – | -643,256 | -100.0% | -0.12% | – | |
| MDVN | Exit | Medivation Inc. | $0 | – | -398,331 | -100.0% | -0.36% | – |
| Exit | Incyte Genomics Notes 4.75% 10/1/2015 144Aconv bonds | $0 | – | -40,446,000 | -100.0% | -3.28% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-05-15
About Baker Brothers Advisors
Baker Brothers Advisors is a well-known investment management firm that specializes in the healthcare sector. The firm was founded in 2000 by brothers Julian and Felix Baker, who are both highly respected in the industry. Julian Baker is the CEO of the firm, while Felix Baker serves as a managing partner.
Baker Brothers Advisors has a reputation for investing in innovative healthcare companies that have the potential to make a significant impact on the industry. The firm has a long-term investment approach and is known for taking large positions in companies that it believes in. Some of the firm's most successful investments include companies such as Pharmacyclics, which was acquired by AbbVie for $21 billion, and Ariad Pharmaceuticals, which was acquired by Takeda for $5.2 billion.
The firm's investment strategy is led by its Chief Investment Officer, Dr. Robert Duggan, who has a background in both medicine and finance. Dr. Duggan is known for his ability to identify promising healthcare companies and for his willingness to take risks on early-stage companies.
Overall, Baker Brothers Advisors is a highly respected investment management firm that has a proven track record of success in the healthcare sector. While the firm's investment approach may not be suitable for all investors, those who are interested in the healthcare sector may want to consider Baker Brothers Advisors as a potential investment opportunity.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Incyte Corporation | 42 | Q3 2023 | 37.6% |
| ACADIA Pharmaceuticals Inc. | 42 | Q3 2023 | 10.9% |
| Biomarin Pharmaceuticals Inc. | 42 | Q3 2023 | 5.9% |
| BioCryst Pharmaceuticals, Inc. | 42 | Q3 2023 | 1.7% |
| Cerus Corporation | 42 | Q3 2023 | 0.9% |
| Insmed Incorporated | 42 | Q3 2023 | 0.4% |
| Mirati Therapeutics, Inc. | 41 | Q3 2023 | 1.8% |
| Bluebird Bio Inc. | 41 | Q3 2023 | 0.3% |
| Heron Therapeutics, Inc. | 39 | Q3 2023 | 1.5% |
| ChemoCentryx, Inc. | 37 | Q3 2022 | 0.6% |
View Baker Brothers Advisors's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | August 17, 2023 | 9,469,838 | 20.0% |
| Mereo Biopharma Group plc | August 10, 2023 | 14,604,391 | 2.2% |
| Verastem, Inc. | August 10, 2023 | ? | ? |
| TScan Therapeutics, Inc. | June 02, 2023 | 2,793,938 | 6.5% |
| ACADIA PHARMACEUTICALS INC | May 24, 2023 | 43,084,280 | 26.5% |
| INCYTE CORP | March 15, 2023 | 36,280,967 | 16.3% |
| Seagen Inc. | March 13, 2023 | 46,985,656 | 25.1% |
| Talis Biomedical Corp | March 10, 2023 | 37,569,140 | 66.2% |
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 6,384,013 | 9.9% |
| Merus N.V. | February 14, 2023 | ? | ? |
View Baker Brothers Advisors's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-23 |
| SC 13D/A | 2024-04-23 |
| 4 | 2024-04-22 |
| 3 | 2024-04-18 |
| SC 13D | 2024-04-18 |
| 3 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| SC 13D | 2024-04-01 |
View Baker Brothers Advisors's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.